KR960033469A - 단일주사 백신 제형 - Google Patents
단일주사 백신 제형 Download PDFInfo
- Publication number
- KR960033469A KR960033469A KR1019950005424A KR19950005424A KR960033469A KR 960033469 A KR960033469 A KR 960033469A KR 1019950005424 A KR1019950005424 A KR 1019950005424A KR 19950005424 A KR19950005424 A KR 19950005424A KR 960033469 A KR960033469 A KR 960033469A
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- antigen
- microparticle
- mixture
- microparticles
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 18
- 238000002347 injection Methods 0.000 title claims abstract 7
- 239000007924 injection Substances 0.000 title claims abstract 7
- 238000009472 formulation Methods 0.000 title claims abstract 6
- 229960005486 vaccine Drugs 0.000 title claims abstract 4
- 239000011859 microparticle Substances 0.000 claims abstract 14
- 239000000427 antigen Substances 0.000 claims abstract 11
- 102000036639 antigens Human genes 0.000 claims abstract 11
- 108091007433 antigens Proteins 0.000 claims abstract 11
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract 5
- 239000004621 biodegradable polymer Substances 0.000 claims abstract 5
- 239000011248 coating agent Substances 0.000 claims abstract 4
- 238000000576 coating method Methods 0.000 claims abstract 4
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- -1 polyoxyethylene Polymers 0.000 claims 3
- 239000011164 primary particle Substances 0.000 claims 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical group 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 235000017060 Arachis glabrata Nutrition 0.000 claims 1
- 244000105624 Arachis hypogaea Species 0.000 claims 1
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 1
- 235000018262 Arachis monticola Nutrition 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010008631 Cholera Diseases 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000019483 Peanut oil Nutrition 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 235000019485 Safflower oil Nutrition 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 208000037386 Typhoid Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 235000012716 cod liver oil Nutrition 0.000 claims 1
- 239000003026 cod liver oil Substances 0.000 claims 1
- 239000008162 cooking oil Substances 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 235000005687 corn oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 235000013681 dietary sucrose Nutrition 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000008157 edible vegetable oil Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 235000010446 mineral oil Nutrition 0.000 claims 1
- 239000002480 mineral oil Substances 0.000 claims 1
- 229940042472 mineral oil Drugs 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 239000004006 olive oil Substances 0.000 claims 1
- 235000008390 olive oil Nutrition 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- 239000000312 peanut oil Substances 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 235000005713 safflower oil Nutrition 0.000 claims 1
- 239000003813 safflower oil Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000003549 soybean oil Substances 0.000 claims 1
- 235000012424 soybean oil Nutrition 0.000 claims 1
- 229940032094 squalane Drugs 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000008297 typhoid fever Diseases 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract 1
- 239000011163 secondary particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
본 발명은 항원을 수용성 고분자로 일차 코팅하고 제조된 일차 입자를 생분해성 고분자로 이차 코팅한 미세입자 및 이를 주사제 용액에 분산시킨 백신 제형으로서 체내에서 수개월에 걸쳐 펄스(pulse) 또는 연속적으로 항원을 방출함으로써 단일주사로 면역을 완성시키는 단일주사 백신 제형에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (19)
- 단일 또는 혼합 항원을 수용성 고분자로 일차 코팅하고, 제조된 일차 입자를 소수성인 생분해성 고분자로 이차 코팅하여 제조된 입경 0.5~300㎛의 미세입자.
- 제1항에 있어서, 상기 항원이 약독화(attenuated) 되었거나 죽은(killed) 항원 또는 유전자 재조합(recombinant) 항원인 미세입자.
- 제1항에 있어서, 상기 항원이 항원 자체이거나 항원과 보조제 또는 무기염의 혼합물인 미세입자.
- 제1항에 있어서, 상기 항원인 간염, 디프테리아, 수두, 장티푸스, 백일해, 파상풍, 결핵, 살모넬라증, 콜레라, HIV, 허피스, 황열, 홍역, 회백수염, 풍진, 유행성 이하선염, 광견병, 플라크, 주혈흡충병, 인플루엔자, 종양, 트리파노소마병, 레이슈마니아증, 나병, 수막염, 및 말라리아 중 하나 이상의 질병을 예방할 수 있는 항원인 미세입자.
- 제3항에 있어서, 상기 보조제가 앨럼(alum), 뮤라밀 디펩티드(muramyl dipeptide), 뮤라밀 트리펩티드(muramyl tripeptide)와 이들의 유도체, 타이모신 알파(tymosin alpha), 모노포스포릴 리피드 A(monophosphoryl lipid A), 사포닌(saponins), 면역자극 복합체(immunostimulating complex), 폴리옥시에틸렌(polyoxyethylene)과 폴리옥시프로필렌(polyoxypropylene)의 공중합체 같은 고분자전해질(polyeletroyte) 또는 이들의 혼합물인 미세입자.
- 제1항에 있어서, 상기 수용성 고분자의 양이 항원의 중량을 기준으로 1~50배인 미세입자.
- 제1항에 있어서, 상기 수용성 고분자가 당류, 단백질, 아미노산 또는 이들의 혼합물인 미세입자.
- 제7항에 있어서, 상기 당류가 셀룰로즈, 글루코즈, 크실로우즈, 갈락토오즈, 프럭토오즈, 락토오즈, 말토오즈, 사카로오즈, 알지네이트, 덱스트란, 히아루론산, 콘드로이틴 설페이트 또는 이들의 혼합물인 미세입자.
- 제8항에 있어서, 상기 셀룰로즈가 하이드록시 프로필 셀룰로즈, 카복시메틸 셀룰로즈, 소디움 카복시메틸 셀룰로즈 또는 이들의 혼합물인 미세입자.
- 제7항에 있어서, 상기 단백질이 젤라틴, 알부민 또는 이들의 혼합물인 미세입자.
- 제7항에 있어서, 상기 아미노산이 글리신, 알리닌, 글루탐산, 아르기닌, 리신, 또는 이들의 염 또는 혼합물인 미세입자.
- 제1항에 있어서, 상기 일차 입자의 입경이 0.1~200㎛인 미세입자.
- 제1항에 있어서, 상기 생분해성 고분자의 양이 일차 입자의 중량을 기준으로 1~100배인 미세입자.
- 제1항에 있어서, 상기 생분해성 고분자가 폴리글라이코라이드, 폴리락타이드, 글라이코라이드와 락타이드의 공중합체 또는 이들의 혼합물인 미세입자.
- 제1항에 있어서, 상기 생분해성 고분자가 코폴리옥살레이트, 폴리카프로락톤, 락타이드와 카프로락톤의 공중합체, 폴리에스터라마이드, 폴리오르토에스테르, 폴리베타하이드록시부티르산, 폴리안하이드라이드 또는 이들의 혼합물인 미세입자.
- 제1항 내지 제15항 중 어느 한 항의 미세입자 또는 이들의 혼합물을 주사제 용액에 분산시킨 단일주사 백신 제형.
- 제16항에 있어서, 상기 주사제 용액이 완충용액 자체이거나, 분산제 또는 방부제를 포함하는 완충용액인 제형.
- 제17항에 있어서, 상기 주사제 용액이 식용유, 미네랄 오일(mineral oil), 스쿠알렌(squalene), 스쿠알란(squalane), 대구 간유(cod liver oil), 모노(mono)-, 디(di)- 및 트리글리세라이드(triglyceride) 또는 이들의 혼합물인 제형.
- 제18항에 있어서, 상기 식용유가 옥배유(corn oil), 호마유(sesame oil), 올리브유(olive oil), 대두유(soybean oil), 홍화유(safflower oil), 면실유(cotton seed oil), 땅콩유(peanut oil) 또는 이들의 혼합물인 제형.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019950005424A KR100201352B1 (ko) | 1995-03-16 | 1995-03-16 | 단일주사 백신 제형 |
| US08/613,830 US5753234A (en) | 1995-03-16 | 1996-03-11 | Single-shot vaccine formulation |
| MXPA/A/1996/000938A MXPA96000938A (en) | 1995-03-16 | 1996-03-12 | Single application vaccination formulation |
| TW085103077A TW495361B (en) | 1995-03-16 | 1996-03-14 | Single-shot vaccine formulation |
| BR9601032A BR9601032A (pt) | 1995-03-16 | 1996-03-15 | Micropartícula e formulação de vacina de dose única |
| PE1996000176A PE57797A1 (es) | 1995-03-16 | 1996-03-15 | Formulacion para vacunas en dosis unica |
| JP8085962A JP2739570B2 (ja) | 1995-03-16 | 1996-03-15 | 単一注射ワクチン剤形 |
| CNB961027282A CN1213736C (zh) | 1995-03-16 | 1996-03-15 | 一次注射疫苗的配制品 |
| ARP960101761A AR002969A1 (es) | 1995-03-16 | 1996-03-15 | UNA MICROPARTICULA DE 0,5 A 300 µM DE TAMANO PREPARADA POR EL RECUBRIMIENTO DE UN ANTIGENO CON UNA SUSTANCIA SOLUBLE EN AGUA Y EL RECUBRIMIENTO DEL NUCLEO OBTENIDO CON UN POLIMERO BIODEGRADABLE; Y UNA FORMULACION DE VACUNA DE DOSIS UNICA PREPARADA POR LA DISPERSION DE DICHA MICROPARTICULA EN UN MEDIO DE INYECCION |
| CA002171881A CA2171881A1 (en) | 1995-03-15 | 1996-03-15 | Single-shot vaccine formulation |
| EP96104177A EP0737472A1 (en) | 1995-03-16 | 1996-03-15 | Single-shot vaccine formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019950005424A KR100201352B1 (ko) | 1995-03-16 | 1995-03-16 | 단일주사 백신 제형 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960033469A true KR960033469A (ko) | 1996-10-22 |
| KR100201352B1 KR100201352B1 (ko) | 1999-06-15 |
Family
ID=19409875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950005424A KR100201352B1 (ko) | 1995-03-15 | 1995-03-16 | 단일주사 백신 제형 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5753234A (ko) |
| EP (1) | EP0737472A1 (ko) |
| JP (1) | JP2739570B2 (ko) |
| KR (1) | KR100201352B1 (ko) |
| CN (1) | CN1213736C (ko) |
| AR (1) | AR002969A1 (ko) |
| BR (1) | BR9601032A (ko) |
| CA (1) | CA2171881A1 (ko) |
| PE (1) | PE57797A1 (ko) |
| TW (1) | TW495361B (ko) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| KR0162872B1 (ko) * | 1996-04-01 | 1998-12-01 | 김은영 | 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법 |
| KR100236771B1 (ko) * | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
| US7276251B2 (en) * | 1997-04-01 | 2007-10-02 | Lg Life Sciences, Ltd., Inc. | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
| TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
| US6156347A (en) * | 1998-01-21 | 2000-12-05 | Bio-Dar Ltd. | Controlled release chromium picolinate |
| US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
| GB9819272D0 (en) * | 1998-09-03 | 1998-10-28 | Andaris Ltd | Microparticles |
| KR100359252B1 (ko) * | 1999-12-21 | 2002-11-04 | 주식회사 엘지생명과학 | 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제 |
| DK1071407T3 (da) | 1999-01-18 | 2014-10-20 | Lg Life Sciences Ltd | Lipofile mikropartikler indeholdende et proteinlægemiddel eller et antigen og formulering omhandlende samme |
| US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
| US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| CA2383814C (en) * | 1999-09-03 | 2010-08-17 | Sigma-Tau Healthscience S.P.A. | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
| GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
| WO2001058466A1 (en) * | 2000-02-08 | 2001-08-16 | Institute Of Molecular Agrobiology | Biodegradable and biocompatible polymeric microspheres encapsulating salmonella enteritidisbacteria |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
| US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| DE60136002D1 (de) | 2000-10-06 | 2008-11-13 | Pacira Pharmaceuticals Inc | Parenteral verabreichbare mikropartikel-zubereitung mit kontrollierter freisetzung |
| SE517421C2 (sv) | 2000-10-06 | 2002-06-04 | Bioglan Ab | Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav |
| SE517422C2 (sv) * | 2000-10-06 | 2002-06-04 | Bioglan Ab | Farmaceutiskt acceptabel stärkelse |
| SE518008C2 (sv) * | 2000-11-16 | 2002-08-13 | Bioglan Ab | Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma |
| SE518007C2 (sv) | 2000-11-16 | 2002-08-13 | Bioglan Ab | Förfarande för framställning av mikropartiklar |
| IL155959A0 (en) | 2000-11-28 | 2003-12-23 | Fmc Corp | Edible pga (propylene glycol alginate) coating composition |
| US20070142325A1 (en) * | 2001-01-08 | 2007-06-21 | Gustavsson Nils O | Starch |
| JP2006512401A (ja) * | 2001-06-05 | 2006-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ナノエマルジョンワクチン |
| US7030127B2 (en) * | 2001-06-29 | 2006-04-18 | Ethicon, Inc. | Composition and medical devices utilizing bioabsorbable polymeric waxes |
| US7034037B2 (en) * | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
| US6967234B2 (en) * | 2002-12-18 | 2005-11-22 | Ethicon, Inc. | Alkyd-lactone copolymers for medical applications |
| US7105181B2 (en) * | 2001-10-05 | 2006-09-12 | Jagotec, Ag | Microparticles |
| SE0201599D0 (sv) * | 2002-03-21 | 2002-05-30 | Skyepharma Ab | Microparticles |
| US7005136B2 (en) | 2002-03-29 | 2006-02-28 | Ethicon, Inc. | Bone replacement materials utilizing bioabsorbable liquid polymers |
| US7326426B2 (en) * | 2002-03-29 | 2008-02-05 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable liquid polymers |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| KR100479735B1 (ko) * | 2002-05-25 | 2005-03-30 | 이현철 | 대식세포특이 나노입자-면역조절제-면역원 복합체를이용한 치아우식증을 예방하는 비경구용 백신 |
| US7368125B2 (en) * | 2002-06-05 | 2008-05-06 | Ethicon, Inc. | Amphiphilic polymers for medical applications |
| US7026374B2 (en) * | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
| US7101566B2 (en) * | 2002-06-28 | 2006-09-05 | Ethicon, Inc. | Polymer coated microparticles for sustained release |
| FR2842737B1 (fr) * | 2002-07-25 | 2006-01-27 | Centre Nat Rech Scient | Particules revetues en surface de hyaluronane ou d'un de ses derives et leur utilisation a titre de vecteurs biologiques pour des matieres actives |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| US6872799B2 (en) | 2002-12-18 | 2005-03-29 | Ethicon, Inc. | Functionalized polymers for medical applications |
| US6866860B2 (en) | 2002-12-19 | 2005-03-15 | Ethicon, Inc. | Cationic alkyd polyesters for medical applications |
| US20040120981A1 (en) * | 2002-12-20 | 2004-06-24 | Aruna Nathan | Crosslinked alkyd polyesters for medical applications |
| CA2510320C (en) * | 2002-12-20 | 2012-10-09 | St. James Associates Llc/Faber Research Series | Coated particles for sustained-release pharmaceutical administration |
| US20070160622A1 (en) * | 2005-12-07 | 2007-07-12 | Medivas, Llc | Method for assembling a polymer-biologic delivery composition |
| US7446131B1 (en) * | 2004-06-10 | 2008-11-04 | The United States Of America As Represented By The Secretary Of Agriculture | Porous polymeric matrices made of natural polymers and synthetic polymers and optionally at least one cation and methods of making |
| KR100729954B1 (ko) | 2004-12-01 | 2007-06-20 | 주식회사 엘지생명과학 | Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법 |
| EP1726299A3 (en) * | 2005-05-27 | 2007-04-18 | StratoSphere Pharma AB | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture |
| EP1933881B1 (en) * | 2005-09-22 | 2019-03-13 | Medivas, LLC | Solid polymer delivery compositions and methods for use thereof |
| CA2623198C (en) | 2005-09-22 | 2014-08-05 | Medivas, Llc | Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use |
| CA2670355A1 (en) * | 2005-11-21 | 2008-04-24 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
| EP2019645A4 (en) * | 2006-05-02 | 2013-03-06 | Medivas Llc | RELEASE OF OPHTHALMOLOGICAL ACTIVITIES OUTSIDE OR WITHIN THE EYE |
| WO2007133616A2 (en) * | 2006-05-09 | 2007-11-22 | Medivas, Llc | Biodegradable water soluble polymers |
| US20090029937A1 (en) * | 2007-07-24 | 2009-01-29 | Cornell University | Biodegradable cationic polymer gene transfer compositions and methods of use |
| US9415006B2 (en) * | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
| EP2323671A4 (en) * | 2008-08-13 | 2012-09-26 | Medivas Llc | BIODEGRADABLE AABB POLY (DEPSIPEPTIDE) POLYMERS AND METHOD FOR THEIR USE |
| US20110020392A1 (en) * | 2008-10-14 | 2011-01-27 | Salubrious Pharmaceutical, Llc | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| US8721583B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8221480B2 (en) | 2008-10-31 | 2012-07-17 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8788211B2 (en) * | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
| US8551505B2 (en) * | 2008-10-31 | 2013-10-08 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| US8731841B2 (en) * | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8545856B2 (en) * | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
| US20100111857A1 (en) * | 2008-10-31 | 2010-05-06 | Boyden Edward S | Compositions and methods for surface abrasion with frozen particles |
| US8725420B2 (en) * | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8849441B2 (en) * | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8762067B2 (en) * | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
| US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8409376B2 (en) | 2008-10-31 | 2013-04-02 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US20100111834A1 (en) * | 2008-10-31 | 2010-05-06 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Compositions and methods for therapeutic delivery with frozen particles |
| US8603494B2 (en) * | 2008-10-31 | 2013-12-10 | The Invention Science Fund I, Llc | Compositions and methods for administering compartmentalized frozen particles |
| US9060934B2 (en) * | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9072688B2 (en) * | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8603495B2 (en) * | 2008-10-31 | 2013-12-10 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8545857B2 (en) * | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for administering compartmentalized frozen particles |
| US8545855B2 (en) * | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8731840B2 (en) * | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050070B2 (en) * | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8798932B2 (en) * | 2008-10-31 | 2014-08-05 | The Invention Science Fund I, Llc | Frozen compositions and methods for piercing a substrate |
| ES2566646T3 (es) * | 2009-06-16 | 2016-04-14 | The Regents Of The University Of Michigan | Vacunas en nanoemulsión |
| EP2515864A4 (en) * | 2009-12-23 | 2013-09-11 | Psivida Inc | DELAYED RELEASE DELIVERY DEVICES |
| CN103118691B (zh) | 2010-08-23 | 2016-08-24 | 康干细胞生物科技有限公司 | 预防和治疗免疫病变和炎性疾病的包括用nod2激动剂处理的干细胞或其培养物的药物组合物 |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| AU2012230894B2 (en) | 2011-03-23 | 2017-01-05 | Elixirgen, Llc | Compositions and methods for enhancing the pluripotency of stem cells |
| JP6129155B2 (ja) | 2011-04-12 | 2017-05-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 同種移植片拒絶反応を抑制する方法 |
| US9932560B2 (en) | 2011-05-13 | 2018-04-03 | Elixirgen, Llc | Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells |
| US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
| EP2723800B1 (en) | 2011-06-23 | 2015-10-07 | DSM IP Assets B.V. | Micro- or nanoparticles comprising a biodegradable polyesteramide copolymer for use in the delivery of bioactive agents |
| JP6099098B2 (ja) * | 2011-11-17 | 2017-03-22 | 国立大学法人富山大学 | 生理活性物質徐放制御組成物 |
| EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | NANOPARTICLES FOR THE TREATMENT OF ALLERGIES |
| EP2968392B1 (en) | 2013-03-15 | 2020-08-05 | Elixirgen Therapeutics, Inc. | Methods of using zscan4 for rejuvenating human cells |
| AU2014235854B2 (en) | 2013-03-21 | 2019-04-11 | Eupraxia Pharmaceuticals USA LLC | Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith |
| MX2015013894A (es) | 2013-04-03 | 2015-12-11 | Allertein Therapeutics Llc | Composiciones de nanoparticulas novedosas. |
| EP2805708A1 (en) * | 2013-05-22 | 2014-11-26 | UCB Pharma, S.A. | Methods to produce particles comprising therapeutic proteins |
| US20160090415A1 (en) * | 2013-05-22 | 2016-03-31 | Ucb Biopharma Sprl | Methods to produce particles comprising therapeutic proteins |
| EP3060238A4 (en) | 2013-10-21 | 2017-06-07 | Salk Institute for Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
| US10287334B2 (en) | 2014-03-07 | 2019-05-14 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain |
| US10434071B2 (en) | 2014-12-18 | 2019-10-08 | Dsm Ip Assets, B.V. | Drug delivery system for delivery of acid sensitivity drugs |
| PL3206672T3 (pl) | 2015-10-27 | 2018-09-28 | Eupraxia Pharmaceuticals Inc. | Preparaty o przedłużonym uwalnianiu środków znieczulających miejscowo |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
| CN107375921B (zh) * | 2017-06-12 | 2019-10-29 | 商丘美兰生物工程有限公司 | 一种甘草皂苷脂质体免疫佐剂及其制备方法 |
| WO2019200163A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| WO2020068862A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
| EP3856914A1 (en) | 2018-09-26 | 2021-08-04 | Krystal Biotech, Inc. | Compositions and methods for the treatment of skin diseases |
| AU2020219343A1 (en) | 2019-02-08 | 2021-08-19 | Krystal Biotech, Inc. | Compositions and methods for delivering CFTR polypeptides |
| WO2020186187A1 (en) | 2019-03-13 | 2020-09-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating bladder and urethra dysfunction and disease |
| AU2020341451A1 (en) | 2019-09-03 | 2022-03-24 | Krystal Biotech, Inc. | Compositions and methods for the treatment of congenital ichthyoses |
| EP4077688A1 (en) | 2019-12-20 | 2022-10-26 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| WO2021225781A2 (en) | 2020-05-07 | 2021-11-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms |
| BR112023020209A2 (pt) | 2021-04-02 | 2023-12-19 | Krystal Biotech Inc | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| US4744933A (en) * | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
| US5417986A (en) * | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| IL84167A (en) * | 1986-10-24 | 1991-04-15 | Southern Res Inst | Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation |
| SE8701479L (sv) * | 1987-04-09 | 1988-10-10 | Carbomatrix Ab | Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5015476A (en) * | 1989-08-11 | 1991-05-14 | Paravax, Inc. | Immunization implant and method |
| IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5344644A (en) * | 1991-08-01 | 1994-09-06 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release |
| GB9310781D0 (en) * | 1993-05-25 | 1993-07-14 | Davis Stanley S | Preparation of microparticles |
| AU1702395A (en) * | 1994-02-17 | 1995-09-04 | Pankaj Modi | Drugs, vaccines and hormones in polylactide coated microspheres |
-
1995
- 1995-03-16 KR KR1019950005424A patent/KR100201352B1/ko not_active IP Right Cessation
-
1996
- 1996-03-11 US US08/613,830 patent/US5753234A/en not_active Expired - Fee Related
- 1996-03-14 TW TW085103077A patent/TW495361B/zh not_active IP Right Cessation
- 1996-03-15 CN CNB961027282A patent/CN1213736C/zh not_active Expired - Fee Related
- 1996-03-15 CA CA002171881A patent/CA2171881A1/en not_active Abandoned
- 1996-03-15 JP JP8085962A patent/JP2739570B2/ja not_active Expired - Fee Related
- 1996-03-15 AR ARP960101761A patent/AR002969A1/es active IP Right Grant
- 1996-03-15 BR BR9601032A patent/BR9601032A/pt not_active Application Discontinuation
- 1996-03-15 PE PE1996000176A patent/PE57797A1/es not_active Application Discontinuation
- 1996-03-15 EP EP96104177A patent/EP0737472A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN1213736C (zh) | 2005-08-10 |
| JP2739570B2 (ja) | 1998-04-15 |
| EP0737472A1 (en) | 1996-10-16 |
| CN1136918A (zh) | 1996-12-04 |
| CA2171881A1 (en) | 1996-09-16 |
| BR9601032A (pt) | 1998-01-06 |
| TW495361B (en) | 2002-07-21 |
| AR002969A1 (es) | 1998-05-27 |
| KR100201352B1 (ko) | 1999-06-15 |
| JPH08253426A (ja) | 1996-10-01 |
| US5753234A (en) | 1998-05-19 |
| PE57797A1 (es) | 1998-03-14 |
| MX9600938A (es) | 1997-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960033469A (ko) | 단일주사 백신 제형 | |
| US5554372A (en) | Methods and vaccines comprising surface-active copolymers | |
| CA2085827C (en) | Adjuvant composition containing synthetic hydrophobic lipopolysaccharide | |
| CA2529363C (en) | Quil a fraction with low toxicity and use thereof | |
| US5032401A (en) | Glucan drug delivery system and adjuvant | |
| US5985284A (en) | Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides | |
| Payne et al. | Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery | |
| US6261573B1 (en) | Immunoadjuvants | |
| AR003006A1 (es) | Composición de vacuna combinada que comprende un polisacarido capsular de haemophilus influenzae b conjugado con una proteina portadora adsorbido sobre fosfato de aluminio y uno u otros antígenos distintos, métodos para producirla, y su uso para preparar un medicamento | |
| CO5210894A1 (es) | Composiciones adyudantes que comprenden una sal de aluminio y un inmunoestimulante | |
| JP2002501904A (ja) | ワクチン | |
| EP2289548A3 (en) | Combined vaccines comprising hepatitis B surface antigen and other antigens | |
| DK93584A (da) | Haemophilus-b-influenza polysaccharid exotoxoid-konjugatvaccine | |
| Jabbal-Gill et al. | Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines | |
| CA2258017C (en) | Immunstimulating lipid formulation | |
| AU688603B2 (en) | Chitosan induced immunopotentiation | |
| CA2086097C (en) | Adjuvants and vaccines | |
| AU769375B2 (en) | Vaccine formulation | |
| BR9916399A (pt) | Método para preparar uma vacina auxiliada por emulsão água/óleo inativada, e, conjunto de partes que podem ser usadas para a preparação de uma vacina auxiliada por emulsão água/óleo inativada | |
| Jabbal-Gill et al. | Polymeric lamellar substrate particles for intranasal vaccination | |
| WO2002043756A3 (es) | Método de obtención de agregados antigénicos y su uso en formulaciones | |
| CA2133108A1 (en) | Pasteurella haemolytica type a-1 bacterin-toxoid vaccine | |
| WO1998039032A1 (es) | Formulaciones inmunopotenciadoras para uso vacunal | |
| Hampl et al. | Adjuvant activity of linear aliphatic polyester and branched aliphatic oligoester microspheres | |
| Brey | Copolymer adjuvants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| J201 | Request for trial against refusal decision | ||
| B701 | Decision to grant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080107 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |